{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:59:28Z","timestamp":1785283168629,"version":"3.55.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jdcr.2025.12.018","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:19:47Z","timestamp":1769818787000},"page":"11-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bimekizumab for recalcitrant pyoderma gangrenosum"],"prefix":"10.1016","volume":"70","author":[{"given":"Christina","family":"Tolete","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8925-1620","authenticated-orcid":false,"given":"Adam","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Calderon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5661-5862","authenticated-orcid":false,"given":"Leonardo","family":"Tjahjono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdcr.2025.12.018_bib1","series-title":"Pyoderma Gangrenosum","author":"Schmieder","year":"2025"},{"key":"10.1016\/j.jdcr.2025.12.018_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/bjd.13670","article-title":"The Treg\/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum","volume":"173","author":"Caproni","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2025.12.018_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00403-024-03689-4","article-title":"Anti-IL 17 biologics and pyoderma gangrenosum - therapeutic or causal?","volume":"317","author":"Wanzenberg","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jdcr.2025.12.018_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdcr.2023.05.002","article-title":"Targeted therapy with ixekizumab in pyoderma gangrenosum: a case series and a literature overview","volume":"37","author":"Kao","year":"2023","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jdcr.2025.12.018_bib5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/bjd\/ljae442","article-title":"The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples","volume":"192","author":"Rastrick","year":"2025","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2025.12.018_bib6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"For the CHAMPION study investigators, efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2025.12.018_bib7","first-page":"1","article-title":"Paradoxical pyoderma gangrenosum secondary to adalimumab successfully treated with methotrexate: a case report","volume":"9","author":"El Morr","year":"2025","journal-title":"Mod Rheumatol Case Rep"},{"issue":"4","key":"10.1016\/j.jdcr.2025.12.018_bib8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2025.12.018_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.12998\/wjcc.v1.i2.74","article-title":"Biological therapy for dermatological manifestations of inflammatory bowel disease","volume":"1","author":"Zippi","year":"2013","journal-title":"World J Clin Cases"},{"issue":"6","key":"10.1016\/j.jdcr.2025.12.018_bib10","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"The Etanercept Psoriasis study group, a global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jdcr.2025.12.018_bib11","first-page":"447","article-title":"Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis","volume":"11","author":"Kowalzick","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"issue":"4","key":"10.1016\/j.jdcr.2025.12.018_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdcr.2025.12.018_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1581996","article-title":"Case report: spesolimab for pyoderma gangrenosum in an undifferentiated oligoarthritis patient receiving anti-IL-17 therapy","volume":"16","author":"Xin","year":"2025","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jdcr.2025.12.018_bib14","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/jdv.18068","article-title":"Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3","volume":"36","author":"Reich","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jdcr.2025.12.018_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ced\/llac117","article-title":"Genetic findings in a patient with paradoxical pyoderma gangrenosum induced by brodalumab","volume":"48","author":"Aromolo","year":"2023","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jdcr.2025.12.018_bib16","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/bjd.15706","article-title":"Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study","volume":"177","author":"Bissonnette","year":"2017","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2025.12.018_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13161","article-title":"Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction","volume":"33","author":"Wollina","year":"2020","journal-title":"Dermatol Ther"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625007118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625007118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:27:21Z","timestamp":1785281241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625007118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":17,"alternative-id":["S2352512625007118"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.12.018","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bimekizumab for recalcitrant pyoderma gangrenosum","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}